Regeneron Begins Human Trials of a Potential COVID-19 Treatment
Another new COVID-19 treatment candidate entered clinical-stage testing on Thursday. Regeneron (NASDAQ: REGN) has started a human trial of REGN-COV2, a pair of antibodies that glom onto SARS-CoV-2, the coronavirus that causes the illness, and stop it from entering host cells.
Earlier this month, Eli Lilly (NYSE: LLY) leaped ahead of Regeneron to become the first company to begin clinical testing of an antibody-based treatment for COVID-19, but REGN-COV2 is the first candidate that uses two antibodies working in concert to clear existing COVID-19 infections.
Image source: Getty Images.
Source Fool.com
